Back to Fallopian Tube Serous Adenocarcinoma

Fallopian Tube Serous Adenocarcinoma — Clinical Trials

MONDO:000620813 active·3 recruitingLast updated: Mar 16, 2026, 2:17 AM

Trial Landscape

Fallopian Tube Serous Adenocarcinoma has a growing clinical research program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment11

Procedure9

Biological Therapy7

7 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Sponsor Types

Academic/Other7NIH5Industry1

Top Sponsors

CanariaBio Inc.

Trial Locations

United States13 trials

South Korea4 trials

Canada3 trials

Puerto Rico3 trials

Japan2 trials

Argentina1 trial

Belgium1 trial

Brazil1 trial

Chile1 trial

Czechia1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

13 Trials

Phase 2Recruiting

NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Mar 2024Est. completion: Dec 2026Updated: Nov 2025

Phase 2Recruiting

NCT04919629

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Apr 2023Est. completion: Apr 2027Updated: May 2025

Early Phase 1Recruiting

NCT05415709

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:Ohio State University Comprehensive Cancer Center

United StatesStarted: Jun 2022Est. completion: Dec 2026Updated: Feb 2026

Phase 3Active, Not Recruiting

NCT04095364

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:NRG Oncology

United StatesStarted: Sep 2019Est. completion: Feb 2028Updated: Jan 2026

Phase 3Active, Not Recruiting

NCT00565851

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2007Est. completion: Jan 2028Updated: Dec 2025

Phase 3Active, Not Recruiting

NCT04498117

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Sponsor:CanariaBio Inc.

United StatesStarted: Aug 2020Est. completion: Aug 2028Updated: Jul 2025

Phase 2Active, Not Recruiting

NCT02345265

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Nov 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02502266

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04739800

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2021Est. completion: Nov 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05114421

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Nov 2021Est. completion: Jan 2026Updated: Aug 2025

Phase 1Active, Not Recruiting

NCT04092270

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2020Est. completion: Jun 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT02068794

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Sponsor:Mayo Clinic

United StatesStarted: Apr 2014Est. completion: Sep 2026Updated: Nov 2025

Early Phase 1Active, Not Recruiting

NCT03943173

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Jun 2019Est. completion: Jun 2027Updated: Feb 2026

Stay informed about clinical trials for Fallopian Tube Serous Adenocarcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 2:17 AM

Fallopian Tube Serous Adenocarcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

13 Trials

Open Trials3

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Active Trials10

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery